Monoklonal gammopati med ubestemt signifikans

Niels Emil Ulrich Hermansen; Trine Silkjær; Charlotte Toftmann Hansen; Thomas Granum Aagaard; Henrik Gregersen

Monoklonal gammopati med ubestemt signifikans

Niels Emil Ulrich Hermansen, Trine Silkjær, Charlotte Toftmann Hansen, Thomas Granum Aagaard, Henrik Gregersen

Hæmatologisk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström's macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

Bidragets oversatte titel	Monoclonal gammopathy of undetermined significance
Originalsprog	Dansk
Artikelnummer	V08190428
Sider (fra-til)	1861-1865
Antal sider	5
Tidsskrift	Ugeskrift for laeger
Vol/bind	182
Udgave nummer	20
Status	Udgivet - 12 okt. 2020

Adgang til dokumentet

https://ugeskriftet.dk/videnskab/monoklonal-gammopati-med-ubestemt-signifikans

Citationsformater

@article{22f2438830ae4726b9aabd15aba6d886,

title = "Monoklonal gammopati med ubestemt signifikans",

abstract = "This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenstr{\"o}m's macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.",

author = "Hermansen, {Niels Emil Ulrich} and Trine Silkj{\ae}r and Hansen, {Charlotte Toftmann} and Aagaard, {Thomas Granum} and Henrik Gregersen",

year = "2020",

month = oct,

day = "12",

language = "Dansk",

volume = "182",

pages = "1861--1865",

journal = "Ugeskrift for laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

TY - JOUR

T1 - Monoklonal gammopati med ubestemt signifikans

AU - Hermansen, Niels Emil Ulrich

AU - Silkjær, Trine

AU - Hansen, Charlotte Toftmann

AU - Aagaard, Thomas Granum

AU - Gregersen, Henrik

PY - 2020/10/12

Y1 - 2020/10/12

N2 - This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström's macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

AB - This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström's macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

M3 - Review

C2 - 32138824

SN - 0041-5782

VL - 182

SP - 1861

EP - 1865

JO - Ugeskrift for laeger

JF - Ugeskrift for laeger

IS - 20

M1 - V08190428

ER -

Monoklonal gammopati med ubestemt signifikans

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater